

Lisa A. Prosser, Ph.D.

Research Associate Professor
Child Health Evaluation and Research Unit
Division of General Pediatrics, University of Michigan Health System
300 N. Ingalls St., Room 6E14, Ann Arbor, MI 48109-5456
Phone: 734-232-1077, Fax: 734-764-2599
Email: lisapros@med.umich.edu

Education

1984-1988	B.A. Mathematics Cornell University, Ithaca, NY
1987	Semester Abroad, School of Mathematical Sciences Queen Mary College, University of London, London, UK
1990-1992	M.S. Management MIT Sloan School of Management, Cambridge, MA
1990-1992	M.S. Technology & Policy Massachusetts Institute of Technology, Cambridge, MA
1995-2000	Ph.D. Health Policy Harvard University, Cambridge, MA

Professional/ Academic Appointments

08/1988-08/1990	Systems Consultant, Andersen Consulting
06/1991-08/1991	Health Policy Analyst, Abt Associates
08/1992-07/1995	Health Care Consultant, The Wilkerson Group
11/1996-06/2000	Research Assistant, Program for the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health
07/2000-03/2001	Instructor, Department of Ambulatory Care & Prevention Harvard Medical School
04/2001-05/2009	Assistant Professor, Department of Ambulatory Care & Prevention Harvard Medical School
02/2006-04/2009	Assistant Professor (secondary), Department of Health Policy and Management Harvard School of Public Health
01/2008-9/2008	Research Scientist, Center for Health Services Research Henry Ford Health System

Professional/ Academic Appointments, cont.

10/2008-present	Lecturer, Department of Population Medicine (formerly Department of Ambulatory Care & Prevention) Harvard Medical School
10/2008-present	Adjunct Associate Professor, Department of Health Policy and Management Harvard School of Public Health
10/2008-present	Research Associate Professor, Department of Pediatrics University of Michigan

Research Interests

My major research interests are (1) economic evaluations of health interventions and (2) valuation of health for economic evaluations. My research focuses on policy-relevant topics concerning the cost-effectiveness of childhood interventions, such as a study of newborn screening for metabolic disorders that assesses how the inclusion of stress and anxiety associated with false positive tests affects the cost-effectiveness of expanded newborn screening programs. My research on the economic impact of influenza vaccination has been used in setting national vaccine policy for children and for prioritizing subgroups in vaccine shortage years. A study underway that assesses public values for avoiding influenza illness will provide data on the relative importance preventing influenza in different age and risk groups.

Another goal in my research is to advance the methods of valuing health for cost-effectiveness analysis, particularly for children's health states. A current project is testing new approaches for valuing temporary health states using a discrete choice experiment.

Grant Support

Principal Investigator: Cost-effectiveness of novel H1N1 influenza vaccination in the United States. Centers for Disease Control and Prevention (via the Joint Initiative for Vaccine Economics). \$158,650 (2009-2010).

Co-Investigator: Measuring preferences for quality of life for child maltreatment outcomes. Centers for Disease Control (via RTI). \$400,000 (2008-2012).

Co-Investigator: TIME: Technology for Immunization Message Enhancement. Centers for Disease Control and Prevention. \$450,000 (2009-2011).

Co-Investigator: Joint initiative in Vaccine Economics III. Centers for Disease Control and Prevention. \$1,279,848 (2007-2010)

Principal Investigator: Cost-effectiveness of live attenuated influenza vaccine for children. Centers for Disease Control and Prevention. \$89,381 (2007-2008).

Grant Support, cont.

Principal Investigator: Economic barriers to obesity prevention and management in children. Harvard Pilgrim Health Care Foundation. \$50,669 (2006-2007).

Co-Investigator: Combining clinical effectiveness and cost effectiveness. Blue Shield Foundation. \$430,000 (2006-2007).

Co-Investigator: Improving primary care to prevent childhood obesity. National Institute of Child Health and Human Development. \$3,102,108 (2005-2010).

Co-Investigator: Methods for evaluating bioterrorism surveillance systems. National Library of Medicine. \$419,430 (2005-2006).

Principal Investigator: Child maltreatment quality of life measurement tool. Centers for Disease Control and Prevention. \$65,004 (2005-2006).

Principal Investigator: Valuing children's health: a review of cost-effectiveness analysis for pediatric health interventions. Department of Ambulatory Care and Prevention Faculty Grant Program. \$27,754 (2005-2006).

Consultant: Health values and treatment of pediatric type 2 diabetes (K-award, Erinn Rhodes). Centers for Disease Control and Prevention (2004-2007).

Co-Investigator: Joint initiative in Vaccine Economics II. Centers for Disease Control and Prevention. \$1,428,261 (2004-2007).

Co-Investigator: Decision analysis of otitis media vaccination strategies (R01). National Institute on Deafness and Other Communication Disorders. \$3,102,108 (2003-2006).

Co-Investigator: Expanded newborn screening for metabolic disorders (R01). ELSI/National Human Genome Research Institute. \$1,766,844 (2003-2006).

Principal Investigator: Are managed care decisions consistent with public preferences? PhRMA Foundation. \$60,000 (2002-2003).

Co-Investigator: Randomized controlled trial to reduce prescribing errors in hypertension (R01). Agency for Healthcare Research and Quality. \$568,684 (2001-2004).

Co-Investigator: Costs and cost-effectiveness of administering influenza vaccination in non-traditional settings through the Joint Initiative in Vaccine Economics. Centers for Disease Control and Prevention. \$1,294,084 (2001-2004).

Co-Investigator: Economic analysis of strategies to reduce influenza morbidity in children. Centers for Disease Control and Prevention (through Vaccine Safety Datalink). \$82,565 (2001-2002).

Co-Investigator: Cost-effectiveness of pneumococcal conjugate vaccine. Centers for Disease Control and Prevention (through Alliance of Community Health Plans). \$200,000 (2000-2002).

Doctoral Student: Cost-effectiveness of interferon beta-1a, interferon beta-1b and glatiramer acetate in patients with relapsing-remitting multiple sclerosis. National MS Society (dissertation fellowship). \$30,000 (1997-1999).

Honors and Awards

1984-1988	Cornell Tradition Fellowship, Miller Scholarship in Mathematics, Newton North High School Music Department Scholarship, Sons of Italy Scholarship, National Merit Scholarship Semifinalist
1991	Master's Thesis Travel Grant, MIT Program on the Pharmaceutical Industry
1992	William J. Stewart, Jr. Award for extracurricular leadership at MIT
1992	MIT Award in recognition of founding Women in Technology & Policy
1995-1997	National Library of Medicine Fellowship
1997-1999	National Multiple Sclerosis Society Doctoral Dissertation Fellowship
1998	Lee B. Lusted Student Prize, Society for Medical Decision Making
1999	National Cholesterol Outcomes Research Excellence (CORE) Award, first place
1999-2000	Thomas O. Pyle Fellowship, Harvard Pilgrim Health Care and Harvard Medical School
2002	50 th Anniversary Scholars in Medicine Award, Harvard Medical School
2005	Best General Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting

Memberships in Professional Societies

1996-present	Member, AcademyHealth
1996-present	Member, Society for Medical Decision Making, Co-Chair, Scientific Review Committee (2008 & 2009 Annual Meetings) Abstract Reviewer (2000-2009)
2000-present	Member, International Health Economics Association
2001-present	Member, International Society for Pharmacoeconomics and Outcomes Research Co-Chair, Contributed Workshops (2006 Annual International Meeting) Abstract Reviewer (2002-2005) Member. Conjoint Analysis Best Practices Task Force (2008 – present)
2006-present	Member, American Society for Health Economists

Editorial Positions, Boards, and Peer-Review Service

1997-present	Ad hoc reviewer, Journal of Health Economics
1999	Ad hoc reviewer, Evaluation and Program Planning
1999	Ad hoc reviewer, Medical Care
2000	Ad hoc reviewer, Annals of Internal Medicine
2000	Ad hoc reviewer, American Journal of Managed Care
2001	Ad hoc reviewer, Pharmacoeconomics
2001	Ad hoc reviewer, Future Drugs
2001-present	Ad hoc reviewer, Medical Decision Making
2003	Ad hoc reviewer, Clinical Therapeutics
2003-present	Ad hoc reviewer, Value in Health
2004-present	Ad hoc reviewer, Vaccine

2004	Ad hoc reviewer, Expert Review of Pharmacoeconomics and Outcomes Research
2004	Ad hoc reviewer, American Journal of Managed Care
2004	Ad hoc reviewer, Pediatrics
2005	Ad hoc reviewer, Archives of Adolescent Medicine
2005-present	Ad hoc reviewer, The Lancet
2005	Ad hoc reviewer, Epidemiologic Reviews
2005	Ad hoc reviewer, Journal of Pediatrics
2006	Ad hoc reviewer, AHRQ
2006-present	Ad hoc reviewer, Health Affairs
2006	Ad hoc reviewer, Arch Dermatology
2006	Ad hoc reviewer, Human Vaccines
2007	Ad hoc reviewer, Health Policy
2007-present	Ad hoc reviewer, New England Journal of Medicine
2008	Ad hoc reviewer, Quality of Life Research
2009	Ad hoc reviewer, JAMA
2008-present	Editorial Board, PharmacoEconomics

Teaching

a. Courses

1996-1998	Teaching Assistant: Management Science Harvard School of Public Health 6 graduate students, 4 hours per week, one-half semester.
1996	Teaching Assistant: Decision Analysis in Clinical Research Harvard School of Public Health 40 graduate students, 4 hours per week, one-half semester.
1996	Teaching Assistant: Decision Analysis for Health and Medical Practices Harvard School of Public Health 40 graduate students, 4 hours per week, one-half semester.
1997	Teaching Assistant: Decision Theory Harvard School of Public Health 8 graduate students, 4 hours per week, one semester.
2003-2005	Guest Lecturer: Methods for Decision Analysis in Public Health and Medicine Harvard School of Public Health 25 students, 6 hours.
2004-2007	Guest Lecturer: Cost-Effectiveness and Cost-Benefit Analysis for Health Program Evaluation Harvard School of Public Health 40 graduate students, 6 hours.
2006	Primary Instructor: Decision Analysis Methods in Public Health and Medicine Harvard School of Public Health 25 students, 14 hours per week, one-half semester.

- 2009 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
32 students, 3 lectures, 12 hours.
- 2009 Lecturer: Pediatric Health Services Research Fellowship Methods Seminars
20 attendees, 1 lecture, 6 hours.

b. Intramural Invited Presentations

- 2000 Department of Ambulatory Care and Prevention, Harvard Medical School,
seminar:
Patient-specific factors in clinical decision-making: the relationship between risk
attitude and treatment choice in patients with multiple sclerosis
- 2000 Harvard Center for Risk Analysis, Harvard School of Public Health, Preference
Working Group seminar:
Patient preferences for treatments and health states in multiple sclerosis
- 2001 Department of Family and Preventive Medicine, University of California San
Diego, seminar:
Introduction to methods for decision analysis in health
- 2002 Dana Farber/ Harvard Cancer Center Outcomes Research Seminar:
Preferences for outcomes prevented by pneumococcal conjugate vaccine:
challenges in using parents as proxies for valuing children's health states
- 2002 Department of Ambulatory Care and Prevention/Pharmaceutical Policy Research
Seminar, Harvard Medical School:
Cost-effectiveness of cholesterol-lowering interventions: challenges of using
CEA in decision-making
- 2003 Department of Ambulatory Care and Prevention, Harvard Medical School,
seminar:
Economic analysis of strategies to reduce influenza morbidity in children
- 2004 Department of Ambulatory Care and Prevention, Harvard Medical School,
seminar:
Are managed care decisions consistent with public preferences?
- 2005 Department of Ambulatory Care and Prevention, Harvard Medical School,
seminar:
The economics of childhood vaccination
- 2006 Harvard Newborn Medicine Epidemiology and Clinical Medicine Conference,
Beth Israel Deaconess Medical Center:
Economic values for newborn screening of metabolic disorders and related
outcomes
- 2006 Dept. of Health Policy and Management, Harvard School of Public Health,
seminar:

Should we vaccinate more children against influenza? Projected health benefits, risks, and cost-effectiveness

2006 Department of Ambulatory Care and Prevention, Harvard Medical School, seminar:
Expanded newborn screening: The effect of false positive test results on quality of life

c. Continuing Medical Education Courses

2003-2005 Lecturer and Core Course Faculty: Cost-effectiveness Analysis for Medical Technologies and Pharmaceuticals (summer executive course), Harvard School of Public Health
40 students, 6 hours

Committee, Organizational, and Volunteer Service

1. Institutional

2002-2006 Member, Joint Committee on the Status of Women, Harvard Medical School
Chair, Subcommittee on Faculty Parental Leave Policy (2002-2005)

2006- Member, Committee on Higher Degrees in Health Policy, Harvard University

2007 Faculty Search Committee, Department of Ambulatory Care & Prevention, Harvard Medical School

2007-present Member, Evidence Review Group, Institute for Clinical and Economic Review

2009-present Member, Pediatric Psychosocial Services Committee, Department of Pediatrics, University of Michigan Health System

2. Regional

2007 Member, Research Grants Review Committee, State of Pennsylvania Department of Health

3. National

2004 Special Reviewer, Research Grants Review Committee, National Eye Institute

2005 Co-Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup to Review Economic Evidence for Prioritizing Target Groups in Vaccine Shortage Years, Centers for Disease Control and Prevention

2005 Member, New Vaccines for Adolescents: National Stakeholders Meeting, Centers for Disease Control and Prevention/National Vaccine Advisory Committee

- 2005-present Member, Database Advisory Panel, National Multiple Sclerosis Society
- 2005-2007 Lead Decision Scientist, Institute for Clinical and Economic Review, Harvard Medical School and Harvard Pilgrim Health Care
- 2006 Member, Peer Review Advisory Panel, Cost-effectiveness of Treatments in Multiple Sclerosis (COSTRIMS) Study
- 2006 Special Reviewer, Research Grants Review Committee, Decision, Risk and Management Sciences Program, National Science Foundation
- 2006 Participant, Review Committee, Project MOVE, Centers for Disease Control and Prevention
- 2006 Member, Fellowship Standards Task Force, International Society for Pharmacoeconomics and Outcomes Research
- 2006-2008 Member, Evidence Review Group, Institute for Clinical and Economic Review, Massachusetts General Hospital
- 2007-present Member, Evidence Review Group, Advisory Committee on Heritable Disorders in Newborns and Children, Health Resources and Services Administration
- 2007 Special Reviewer, Canada Foundation for Innovation
- 2005 Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup to Review Economic Evidence for Vaccinating Healthy Working-Age Adults, Centers for Disease Control and Prevention
- 2008 Reviewer, Special Emphasis Panel, Centers for Disease Control and Prevention
- 2009 Reviewer, Special Emphasis Panel, Agency for Healthcare Research and Quality

Consulting Positions

- 2008- present Visiting Scientist, Methodological expertise in economic evaluation, United BioSource Corporation

Visiting Professorships, Seminars, and Extramural Invited Presentations

Seminars:

- 2007 Initiative on Medication Management, Policy Analysis, Research & Training (IMPART), Dalhousie University, Halifax, Nova Scotia, Canada
Introduction to Markov models (seminar/workshop)

Extramural Invited Presentations:

- 2000 Annual Meeting of the Society for Medical Decision Making
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in multiple sclerosis (podium presentation)
- 2001 Annual Meeting of the Society for Medical Decision Making
Do risk attitudes differ across domains and respondent types? (podium presentation)
- 2003 Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (presentation)
- 2003 National Immunization Program, Centers for Disease Control and Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (research seminar)
- 2004 Ninth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
An economic analysis of rapid tests and antiviral treatments for influenza in children (podium presentation)
- 2005 Tenth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Costs of delivering adult influenza vaccination in non-traditional settings (podium presentation)
- 2005 Advisory Committee on Immunization Practices Influenza Working Group
Using economic information to prioritize subgroups during influenza vaccine shortages (presentation)
- 2006 Annual Meeting of the New England Consortium of Metabolic Programs
Cost-effectiveness of expanded newborn screening (presentation)
- 2007 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations (podium presentation)

- 2007 Center for Health Services Research, Henry Ford Health System
Projected costs, risks, and benefits of influenza vaccination of children (research seminar)
- 2007 Conference on Routine Vaccination Against Influenza for Older Children, Centers for Disease Control and Prevention
Projected health benefits, risks, and cost-effectiveness of influenza vaccination: Children aged 5-17 years (presentation)
- 2007 Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention
Cost-effectiveness of influenza vaccination: updated estimates for children aged 2-4 years (presentation)
- 2008 Child Health Evaluation and Research (CHEAR) Unit, Department of Pediatrics, University of Michigan Medical School
Projected health benefits, risks, and cost-effectiveness of influenza vaccination (research seminar)
- 2008 Annual Conference on Vaccine Research, National Foundation for Infectious Diseases
Cost-effectiveness of universal vaccination, Symposium: Universal Vaccination Against Influenza (symposium speaker)
- 2008 30th Annual Meeting of the Society for Medical Decision Making
Valuing health across the lifespan (podium presentation)
- 2009 2009 Pediatric Academic Societies' Annual Meeting
Valuing health for children and adults (platform presentation)
- 2009 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Eliciting time trade-off amounts for health states in hypothetical individuals of different ages using a discrete choice experiment (podium presentation)
- 2009 Centers for Disease Control and Prevention
Cost-effectiveness of pH1N1 influenza vaccination in the United States (research seminar)

Bibliography

Peer-reviewed Publications:

1. **Prosser LA**, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. *Am J Manag Care*. 2000;6(2):173-179.
2. **Prosser LA**, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Me*. 2000;132(10):768-779.

3. **Prosser LA**, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses (*letter*). *Ann Intern Med* 2001;135(5):383.
4. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. *Med Decis Making*. 2002;22:506-513.
5. Lieu TA, Thompson KM, **Prosser LA**, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines*. 2002;1(4):433-442.
6. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler*. 2003;9:311-319.
7. Wang SJ, Middleton B, **Prosser LA**, Bardon CG, Spurr CD, Carchidi PJ, Kittler AF, Goldszer RC, Fairchild DG, Sussman AJ, Kuperman GJ, Bates DW. A cost-benefit analysis of electronic medical records in primary care. *Am J Med*. 2003;114(5):397-403.
8. **Prosser LA**, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. *Pediatrics*. 2004;113(2):283-290.
9. **Prosser LA**, Lieu TA. Comments on the Prosser et al approach to value disease reduction in children: In reply (*letter*). *Pediatrics*. 2004;114:1375-1376.
10. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health*. 2004;7(5):554-568.
11. **Prosser LA**, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. *Health Qual Life Outcomes*. 2005;3(18):1-16.
12. Simon SR, Majumdar SR, **Prosser LA**, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. *Am J Med*. 2005;118(5):521-528.
13. Gupta RS, Bewtra M, **Prosser LA**, Finkelstein JA. Predictors of hospital charges for children admitted with asthma. *Ambul Pediatr*. 2006;6(1):15-20.
14. Wittenberg E, Halpern E, Divi N, **Prosser LA**, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. *Qual Life Res*. 2006;15(4):645-653.
15. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, **Prosser LA**, Simon SR. Clinical and non-clinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. *J Clin Hypertension*. 2006;8(6):414-419.
16. **Prosser LA**, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. *Emerg Infect Dis*. 2006;12(10):1548-1558.

17. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, **Prosser LA**, Buring JE, Cherkin DC. Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial. *Spine*. 2007;32(2):151-8.
18. **Prosser LA**, Corso PS. Measuring health-related quality of life for child maltreatment: A systematic literature review. *Health Qual Life Outcomes*. 2007;5(1)1-17. Available at: <http://www.hqlo.com/content/5/1/42>.
19. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, **Prosser LA**. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. *J Clin Hyper*. 2007;9(1):15-20.
20. **Prosser LA**, Wittenberg E. Do risk attitudes differ across domains and respondent types? *Med Decis Making*. 2007;27(3):281-287.
21. **Prosser LA**, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations. *Pharmacoeconomics*. 2007;25(9):713-726.
22. Ladapo JA, Neumann PJ, Keren R, **Prosser LA**. Valuing children's health: a comparison of cost-utility analyses for adult and pediatric health interventions (review). *Pharmacoeconomics*. 2007;25(10):817-828.
23. **Prosser LA**, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Wortley PM, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults: Costs and cost-effectiveness. *Pharmacoeconomics*. 2008;26(2):163-178.
24. Ortega-Sanchez IR, Lee GM, Jacobs RJ, **Prosser LA**, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States (review). *Pediatrics*. 2008;121 Suppl 1:S63-78.
25. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, **Prosser LA**. Community and patient values for preventing zoster. *Pharmacoeconomics*. 2008;26(3):235-49.
26. **Prosser LA**, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance for false-positive newborn screening results. *Arch Pediatr Adolesc Med*. 2008;162(9):870-6.
27. O'Brien MA, **Prosser LA**, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen V, Mehta J, Colborne JK, Lieu TA. New vaccines against otitis media: projected benefits and cost-effectiveness. *Pediatrics*. 2009;123(6):1452-1463.
28. **Prosser LA**. Current challenges and future research in measuring preferences for pediatric health outcomes (invited editorial). *J Pediatr*. 2009;155(1):7-9.
29. Wright DR, Wittenberg E, Swan JS, Miksad RA, **Prosser LA**. Methods for measuring temporary health states for cost-utility analyses (review). *Pharmacoeconomics*. 2009; 27(9): 713-23.
30. Lipstein EA, Perrin JM, Waisbren SE, **Prosser LA**. Impact of false-positive newborn metabolic screening results on early health care utilization. *Genetics in Medicine* 2009; 11(10):1-6

31. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, **Prosser LA**. Willingness-to-pay for a quality-adjusted life-year based on community member and patient preferences for temporary health states associated with zoster. *Pharmacoeconomics*. In press.
32. **Prosser LA**, Kong CY, Rusinak D, Waisbren SE. Projected costs, risks, and benefits of expanded newborn screening for MCADD. *Pediatrics*. In press.

Reports (Non-Peer Reviewed)

1. Pearson SD, Ladapo J, **Prosser LA**. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Final appraisal document. Institute for Clinical and Economic Review. November, 2007. Available at: <http://www.icer-review.org/index.php/imrt.html>.
2. Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. A checklist for conjoint analysis applications in health: Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Available at: <http://www.ispor.org/TaskForces/ConjointAnalysisGRP.asp>

Book Chapters

1. **Prosser LA**, Payne K. Discrete Choice. Encyclopedia of Medical Decision Making. Thousand Oaks, CA: SAGE Publications. 2009.

Theses

1. **Prosser LA**. Pharmaceutical research and development: the effects of increased competition on human resource strategies [master's thesis]. Boston (MA): MIT; 1992.
2. **Prosser LA**. Patient preferences and economic considerations in treatment decisions for multiple sclerosis [dissertation]. Cambridge (MA): Harvard University; 2000.

Abstracts

(This section includes only presented abstracts not yet published as peer-reviewed journal articles.)

1. **Prosser LA**, Uyeki TM, Bridges CB, Rego VH, Meltzer M, Schwartz B, Thompson WW, Fukuda K, Lieu TA. An economic analysis of rapid tests and antiviral treatments for influenza in children. *Value in Health*. 2004;3:222-223.
2. **Prosser LA**, Concannon TW, Pearson SD, Hammitt JK. An internet survey of public preferences for characteristics of health interventions. *Med Decis Making*. 2005;25(1):E57.
3. **Prosser LA**, Griffin M, Keren R, Meltzer MI, Ortega-Sanchez I, Herrera G, Messonnier ML, Bridges CB. Using economic evidence to prioritize subgroups during an influenza vaccine shortage. *Med Decis Making*. 2006;26(1):E77.

4. **Prosser LA**, Wittenberg E. Valuing children's health: response issues with using parents as proxies. *Med Decis Making* 2007;25(1):E57.
5. **Prosser LA**, Kong J, Rusinak D, Waisbren SE. Waisbren. Expanded newborn screening: the effect of preferences for false positive test results and dietary treatments on cost-effectiveness. *Med Decis Making*. 2008;25(1):E60.
6. Sandberg EA, **Prosser LA**, Neumann P, Weinstein MC. Health state utilities in children ages 7-10 with attention deficit hyperactivity disorder. *Med Decis Making*. 2008;25(1):E72.
7. Lavelle TA, Uyeki TM, **Prosser LA**. The impact of pediatric adverse events on the cost-effectiveness of oseltamivir. Presented at the 13th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, May 4, 2008, Toronto, ON, Canada.
8. Wright DR, Wittenberg E, Swan JS, Miksad R, **Prosser LA**. A review and critique of methods for measuring temporary health states in cost-utility analyses. Presented at the 13th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, May 5, 2008, Toronto, ON, Canada.
9. Sonnevile K, Lapelle N, Taveras E, Gillman M, **Prosser L**. Economic and other barriers to adopting better nutrition and physical activity behaviors among overweight children. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
10. Sandberg EA, Thompson K, **Prosser LA**, Neumann P, Weinstein MC. The cost-effectiveness of treatments for attention deficit hyperactivity disorder (ADHD) in children ages 7-10. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
11. Wang YC, Cheung AM, Bibbins-Domingo K, **Prosser LA**, Cook NR, Trent SA, Goldman L, Gillman M. Effectiveness of blood pressure screening among adolescents on reducing future burden of coronary heart disease. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
12. **Prosser LA**, Hinrichsen V, Lieu TA. The effect of possible wheezing adverse events on the cost-effectiveness of nasal influenza vaccine in children. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
13. **Prosser LA**, Rusinak D, Payne K, Uyeki T, Kamimoto L, Messonnier M. Valuing health across the lifespan. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
13. **Prosser LA**, Rusinak D, Payne K, Uyeki T, Kamimoto L, Messonnier M. Valuing health for children and adults. Presented at the Pediatric Academic Societies' Annual Meeting, May 2, 2009, Baltimore, MD.
14. Lipstein EA, Perrin JM, Waisbren SE, **Prosser LA**. Impact of False-Positive Newborn Metabolic Screening Results on Early Health Care Utilization. Presented at the Pediatric Academic Societies' Annual Meeting, May 5, 2009, Baltimore, MD.

15. Srivastava R, Barnhart DC, Campbell K, Mahant S, Goldin AB, Mundorff M, Dasgupta R, Dean JM, **Prosser LA**. Fundoplication Versus Gastrojejunal Feeding Tubes To Treat Gastroesophageal Reflux Disease in Children with Neurological Impairment: A Markov Model. Presented at the Pediatric Academic Societies' Annual Meeting, May 5, 2009, Baltimore, MD.
16. **Prosser LA**, Rusinak D, Payne K, Uyeki T, Kamimoto L, Messonnier M. Eliciting time trade-off amounts for health states in hypothetical individuals of different ages using a discrete choice experiment. Presented at the 14th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, May 18, 2009, Orlando, FL.